

The ACT NOW Clinical Practice Survey: Gaps in the Care of Infants With Neonatal Opioid Withdrawal Syndrome

Jessica N. Snowden, MD,^a A. Akshatha, MD, FAAP,^b Robert D. Annett, PhD,^c Margaret M. Crawford, BS, CCRP,^d Abhik Das, PhD,^d Lori A. Devlin, DO, MHA, MSc,^e Rosemary D. Higgins, MD,^f Zhuopei Hu, MS,^g Elizabeth Lindsay, MD,^h Stephanie Merhar, MD,^h Clare Campbell Nesmith, MD,^g Heather Pratt-Chavez, MD,ⁱ Judith Ross, MD,^j Alan E. Simon, MD,^k M. Cody Smith, MD,^l Christine B. Turley, MD,^m Anita Walden, MS,^a Leslie Young, MD,ⁿ Bonny Whalen, MD^o

ABSTRACT



^aDepartment of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas; ^bKapiolani Women and Children's Hospital, Honolulu, Hawaii; ^cUniversity of Mississippi Medical Center, Jackson, Mississippi; ^dRTI International, Research Triangle Park, North Carolina; ^eDepartment of Pediatrics, University of Louisville, Louisville, Kentucky; ^fCollege of Health and Human Services, George Mason University, Fairfax, Virginia; ^gDepartment of Pediatrics, Section of Neonatology, Tulane University, New Orleans, Louisiana; ^hCincinnati Children's Hospital Medical Center, Cincinnati, Ohio; ⁱHealth Sciences Center, University of New Mexico, Albuquerque, New Mexico; ^jNemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware; ^kEnvironmental Influences on Child Health Outcomes Program, National Institutes of Health, Bethesda, Maryland; ^lWest Virginia University Medical Center, Morgantown, West Virginia; ^mDepartment of Pediatrics, College of Medicine, University of South Carolina, Columbia, South Carolina; ⁿUniversity of Vermont Medical Center, Burlington, Vermont; and ^oChildren's Hospital at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

OBJECTIVES: The incidence of neonatal opioid withdrawal syndrome (NOWS) has increased fivefold over the last 10 years. Standardized NOWS care protocols have revealed many improved patient outcomes. Our objective for this study is to describe results of a clinical practice survey of NOWS management practices designed to inform future clinical studies in the diagnosis and management of NOWS.

METHODS: A cross-sectional survey was administered to medical unit directors at 32 Institutional Development Award States Pediatric Clinical Trial Network and 22 Neonatal Research Network sites in the fall of 2017. Results are presented as both the number and percentage of positive responses. Ninety-five percent Wilson confidence intervals (CIs) were generated around estimates, and χ^2 and Fisher's exact tests were used to compare the association between unit type and reporting of each protocol.

RESULTS: Sixty-two responses representing 54 medical centers were received. Most participating NICU and non-ICU sites reported protocols for NOWS management, including NOWS scoring (98% NICU; 86% non-ICU), pharmacologic treatment (92% NICU; 64% non-ICU), and nonpharmacologic care (79% NICU; 79% non-ICU). Standardized protocols for pharmacologic care and weaning were reported more frequently in the NICU (92% [95% CI: 80%–97%] and 94% [95% CI: 83%–98%], respectively) compared with non-ICU settings (64% [95% CI: 39%–84%] for both) ($P < .05$ for both comparisons). Most medical centers reported morphine as first-line therapy (82%; 95% CI: 69%–90%) and level 3 and level 4 NICUs as the location of pharmacologic treatment (83%; 95% CI: 71%–91%).

CONCLUSIONS: Observed variations in care between NICUs and non-ICUs revealed opportunities for targeted interventions in training and standardized care plans in non-ICU sites.

www.hospitalpediatrics.org

DOI:https://doi.org/10.1542/hpeds.2019-0089

Copyright © 2019 by the American Academy of Pediatrics

Address correspondence to Jessica N. Snowden, MD, Institutional Development Award (IDeA) States Pediatric Clinical Trials Network Data Coordinating and Operations Center, University of Arkansas for Medical Sciences, 4301 W Markham St, Slot 721-23, Little Rock, AR 72205. E-mail: jsnowden@uams.edu

HOSPITAL PEDIATRICS (ISSN Numbers: Print, 2154-1663; Online, 2154-1671).

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: The Institutional Development Award States Pediatric Clinical Trials Network is funded by the National Institutes of Health's Office of the Director, as part of the Environmental Influences on Child Health Outcomes Program, under the following grant numbers: UG10D024944, UG10D024945, UG10D024946, UG10D024959, UG10D024958, UG10D024951, UG10D024948, UG10D024943, UG10D024954, UG10D024942, UG10D024952, UG10D024953, UG10D024947, UG10D024950, UG10D024956, UG10D024955, UG10D024949, U240D024957. The National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Center for Advancing Translational Sciences (NCATS) provided support for the Neonatal Research Network (NRN), under the following grant numbers: UG1HD87229, UG1HD68278, U24HD095254, U10HD27880, UG1HD34216, UG1HD53109, UG1HD68244, UG1HD68263, UL1TR42, UG1HD40689, UG1HD87226; UL1TR105, U10HD27851, UL1TR454, UG1HD40492, UL1TR83, UG1HD27853, UG1HD21364, U10HD53089, UL1TR41. Funded by the National Institutes of Health (NIH).

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

Dr Snowden drafted the initial manuscript and managed all revisions; Drs Young, Devlin, Higgins, Das, and Merhar conceptualized and designed the survey; Dr Hu performed all statistical analyses; and all authors contributed to the analysis plan and literature review, which frames the discussion, and approved the final manuscript as submitted.

The incidence of neonatal opioid withdrawal syndrome (NOWS) has increased fivefold over the last decade because of increased opioid use in women of childbearing age.^{1–5} From 1999 to 2014, the prevalence of opioid use disorder among delivery hospitalizations in the United States increased from 1.5 to 6.5 per 1000 events.⁶ The Centers for Disease Control and Prevention recommends that hospitals have protocols to identify and manage infants with NOWS as a public health–level intervention.⁷ Inpatient NOWS care protocols have revealed benefits in improving outcomes, such as shorter time to diagnosis, reduced therapeutic opioid exposure, and decreased length of stay, for infants with NOWS.^{8–16} The number of hospital units implementing standardized care protocols has been examined in surveys during the last 10 years.^{17–19} Patrick et al¹⁷ reported an increase in the number of centers with a protocol for NOWS evaluation and management from 76% to 95% between 2013 and 2014 in NICUs participating in the Vermont Oxford Network. A survey of NICUs by Mehta et al¹⁸ similarly revealed that 72% of NICUs had protocols for NOWS management. Bogen et al¹⁹ performed a survey of US academic and community hospitals in the Academic Pediatric Association’s Better Outcomes through Research for Newborns (BORN) Network in 2015. At that time, 88% of BORN Network sites had NOWS management protocols for addressing medical management, nursing care, pharmacologic treatment, and supportive care.¹⁹ However, these estimates have varied, potentially because of differences in hospitals surveys but also likely because of changes over time, with the most recent estimates from 2015. As the scope of the opioid crisis increases, so also do the number and types of health care providers involved in treating the symptoms of neonatal opioid withdrawal.^{20,21} A more recent reevaluation of the clinical practices guiding the care of infants with NOWS at the institutional level may identify new areas for engagement and intervention to improve the quality of care. In this study, we describe more recent data from a clinical practice survey of NOWS management practices in 54 Institutional

Development Award States Pediatric Clinical Trial Network (ISPCTN) and National Institutes of Health *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) sites designed to inform future clinical trials in the diagnosis and management of NOWS.

METHODS

The ISPCTN and NRN convened a cross-disciplinary team in September 2017 to address the growing neonatal opioid crisis.^{22,23} This collaboration between the ISPCTN and NRN resulted in the formation of the Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) initiative, a research alliance designed to evaluate diagnostic and treatment options for neonates experiencing withdrawal from prenatal opioid exposure. The ACT NOW collaborative is implementing a multifaceted clinical research program designed to fill these gaps, building on clinical practice surveys and observational data collection to direct future clinical trials across the United States in both urban and rural sites.

The ACT NOW Clinical Practice Survey was a cross-sectional, clinical unit–level exploratory survey conducted October 2017 to November 2017. The purpose of the survey was to identify current practice in the ISPCTN and NRN sites that would potentially participate in future ACT NOW clinical trials. The survey content was adapted in part from the 2015 Bogen et al¹⁹ survey of NOWS care and is detailed in Supplemental Table 4. The ISPCTN Data Coordinating and Operations Center (DCOC) sent the survey to principal investigators of 17 ISPCTN and 15 NRN sites with instructions for the survey to be completed by the medical director of any unit caring for infants with NOWS at their associated clinical sites. The ISPCTN DCOC used Research Electronic Data Capture to build the data collection instrument.²⁴ ISPCTN investigators received a unique link to the ACT NOW Clinical Practice Survey that allowed for individual tracking of receipt and response. At the request of the NRN coordinating center, the NRN investigators received a generic link that did not allow for individual tracking of receipt and response

among NRN investigators. For a complete list of participating institutions, please see the Acknowledgments.

Results are presented as both a number and percentage of “yes” responses. The respondent indicated which protocols and/or care measures were in place in their unit for the diagnosis and management of NOWS, including screening protocols, scoring systems used to aid in clinical decision-making, and types and weaning of pharmacologic treatment. They additionally indicated which nonpharmacologic care measures were used, the location of pharmacologic care, and first- and second-line pharmacologic treatments used when pharmacologic treatment was initiated. Respondents self-identified their unit as “NICU/PICU,” “delivery unit,” or “other.” The latter 2 categories were collapsed, and practice data are hereafter displayed as “NICU” and “non-ICU.” Respondents were able to select >1 option in any category and, in some instances, had the option to provide more detail using free text. Ninety-five percent Wilson confidence intervals (CIs) were generated around estimates, and χ^2 and Fisher’s exact tests were used to compare the association between unit type (NICU versus non-ICU) and reporting of each standardized protocol guiding NOWS care in each domain. The statistical software R version 3.5.3 (R Foundation for Statistical Computing, Vienna, Austria) was used for computing statistics and performing tests. No adjustments were made for multiple comparisons.

RESULTS

Sixty-two unit respondents, representing 54 medical centers across 28 states, responded to the ACT NOW Clinical Practice Survey. Thirty-eight ISPCTN unit respondents and 24 NRN units submitted responses, representing 32 ISPCTN medical centers and 22 NRN medical centers. All ISPCTN and NRN investigators responded to the survey for at least 1 unit in their catchment area (100% response rate). Five ISPCTN sites and 2 NRN sites submitted responses from >1 unit within a single medical center. Three centers (1 in New Mexico and 2 in Rhode Island) participate in both the ISPCTN and the NRN; all 3 centers are categorized with

the ISPCTN in this survey on the basis of the initial survey invitation. Respondents self-identified as NICU ($n = 48$) and as delivery unit or other (combined as non-ICU; $n = 14$), which could include mother-infant units, inpatient general pediatric wards, or other units that provide care for infants with NOWS.

Standardized Care Protocols for NOWS by Inpatient Setting

Most of the participating NICU and non-ICU sites reported standard care protocols for many NOWS management domains (Table 1). NICU representatives reported protocols for 79% to 98% of domains queried; by inspection, non-ICU units appeared slightly less likely to report protocols for NOWS care in the queried domains (64%–86%). Standardized protocols for pharmacologic care and weaning were reported more frequently in the NICU setting (92% [95% CI: 80%–97%] and 94% [95% CI: 83%–98%], respectively) compared with in the non-ICU settings (64% [95% CI: 39%–84%] for both) ($P < .05$ for both comparisons). Tools for monitoring infant withdrawal symptoms are characterized in Table 2. Seventy-three percent (95% CI: 59%–83%) of respondents used the modified Finnegan scoring system, 4% (95% CI: 1%–14%) used the Neonatal Withdrawal Inventory (a Finnegan-related scoring system), and the remainder used either the original

Finnegan or the Neonatal Abstinence Scoring System (another Finnegan-related system).^{25–27}

Nonpharmacologic Care

Seventy-nine percent of both NICU and non-ICU sites reported having policies that support implementation of nonpharmacologic therapies for stabilization and treatment of infants with in utero opioid exposure (Table 1). Respondents identified all components of nonpharmacologic care used at their site. A summary of the reported nonpharmacologic care practices is presented in Table 3. Respondents from NICUs were significantly more likely to report using “cuddlers” (75% of NICUs [95% CI: 61%–85%] vs 43% of non-ICUs [95% CI: 21%–67%]; $P < .05$) and breastfeeding (98% [95% CI: 89%–100%] vs 71% [45% to 88%]; $P < .05$) as nonpharmacologic treatment of NOWS symptoms than respondents from non-ICUs. Swaddling (98% of NICUs and 86% of non-ICUs), positioning and comfort measures (88% of NICUs and 79% of non-ICUs), avoiding overstimulation (94% of NICUs and 86% of non-ICUs), and rooming-in (60% of NICUs and 64% of non-ICUs) were the most frequently reported nonpharmacologic care measures. Infant massage (21% of NICUs and 14% of non-ICUs) and high-calorie nutrition (40% of NICUs and 43% of non-ICUs) were reported less often. Seven units selected “other” and

used free text to describe nonpharmacologic care, such as elemental formula if no breast milk was available, ear muffs, dark room, single room, skin-to-skin contact, environmental control, high-calorie nutrition only if significant weight loss was present, and nonpharmacologic therapies as directed by other providers (eg, physical or occupational therapy and child-life consultation).

Pharmacologic Treatment

Respondents could select multiple locations in which pharmacologic treatment of NOWS occurred in the medical center. Overall, medical centers reported that pharmacologic care for infant exposed to opioids occurred in level 3 and level 4 NICUs (83%; 95% CI: 71%–91%) more frequently than they reported pharmacologic care occurring in other locations. Specifically, 48% (95% CI: 35%–61%) of medical centers reported pharmacologic treatment in level 2 intensive care nurseries, 15% reported pharmacologic treatment while rooming-in (95% CI: 8%–27%), 13% reported pharmacologic treatment on the pediatric ward (95% CI: 6%–24%), 7% reported pharmacologic treatment in the newborn nursery (95% CI: 3%–18%), and 7% reported pharmacologic treatment in other special NOWS care locations within the hospital (95% CI: 3%–18%). Two medical centers indicated “other” as a location of pharmacologic treatment and commented that care was provided in a dedicated NOWS unit within the NICU or in a rooming-in environment unless there were other medical indications for intensive care or no bed space available.

Morphine was the most commonly reported first-line therapy (82% of all reporting medical centers [95% CI: 69%–90%]; 40 NICUs and 9 non-ICUs); however, some centers use >1 drug as first-line therapy. Methadone (22% of all reporting medical centers [95% CI: 13%–35%]; 11 NICUs and 1 non-ICU), buprenorphine (4% of all reporting medical centers [95% CI: 1%–13%]; 2 NICUs), and clonidine (2% of all reporting medical centers [95% CI: 0%–10%]; 1 NICU) were also reported. The most commonly reported second-line pharmacologic therapies were clonidine

TABLE 1 Number and Percentage of Units Reporting a Standardized Protocol in Each Domain

Does Your Unit Have a Standardized Protocol Specific to the Following Domains?	NICU		Non-ICU	
	No. Units ($n = 48$)	Units, % (95% CI)	No. Units ($n = 14$)	Units, % (95% CI)
Screening for maternal substances	38	79 (66–88)	9	64 (39–84)
Nonpharmacologic treatment	38	79 (66–88)	11	79 (52–92)
NOWS scoring	47	98 (89–100)	12	86 (60–96)
Breastfeeding for infants with in utero opioid exposure	43	90 (78–95)	11	79 (52–92)
Duration of observation for infants with in utero opioid exposure	41	85 (73–93)	12	86 (60–96)
Pharmacologic treatment of NOWS ^a	44	92 (80–97)	9	64 (39–84)
Weaning of pharmacologic therapy ^a	45	94 (83–98)	9	64 (39–84)

There were 62 responding units in total. Five sites selected “other” and reported standardized protocols such as mandated reporting, family involvement in assessments, NOWS assessments on the infant’s schedule, parent information, prenatal consults, discharge planning, and a program to influence staff attitudes.

^a $P < .05$; Fisher’s exact test was used to compare the percentage of NICUs that responded affirmatively to each question with the percentage of non-ICUs that responded affirmatively to each question.

TABLE 2 Number and Percentage of Units Using Original Finnegan Scoring, Modified Finnegan Scoring, the Neonatal Withdrawal Inventory, the Neonatal Abstinence Scoring System, or Other Scoring Scales to Aid in Decision-making Regarding Management of Infants With NOWS

What Scoring System Does Your Unit Use to Aid in Management of Infants With In Utero Opiate Exposure?	NICU		Non-ICU	
	No. Units (n = 48)	Units, % (95% CI)	No. Units (n = 14)	Units, % (95% CI)
Finnegan scoring, original	8	17 (9–30)	2	14 (4–40)
Finnegan scoring, modified	35	73 (59–83)	10	71 (45–88)
NWI	2	4 (1–14)	0	0 (0–22) ^a
NASS	5	10 (5–22)	1	7 (1–31)

Adapted from Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacotherapy. In: Nelson NM, ed. *Current Therapy in Neonatal-Perinatal Medicine*. 2nd ed. Hamilton, Canada: BC Decker; 1990; Zahorodny W, Rom C, Whitney W, et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. *J Dev Behav Pediatr*. 1998;19(2):89–93; and Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. *Addict Dis*. 1975;2(1–2):141–158. There were 62 responding units in total. Units may have reported the use of >1 scoring system. Two non-ICUs reported other scoring scales to aid in decision-making; 1 of these units reported using the Eat, Sleep, Console assessment method. No statistical differences were observed between the percentage of NICUs that responded affirmatively to each question and the percentage of non-ICUs that responded affirmatively to each question. NASS, Neonatal Abstinence Scoring System; NWI, Neonatal Withdrawal Inventory.

^a Modified Wilson CI.

(59% of all reporting medical centers [95% CI: 46%–71%]; 28 NICUs and 4 non-ICUs) and phenobarbital (57% of all reporting medical centers [95% CI: 44%–70%]; 26 NICUs and 5 non-ICUs), and, as with first-line therapy, some centers reported using >1 drug for second-line therapy. Methadone (11% of all reporting medical centers [95% CI: 5%–22%]; 6 NICUs) and morphine (6% of all reporting medical centers [95% CI: 2%–15%]; 3 NICUs) were also reported by a small number of sites as second-line

therapy. Other second-line therapies included buprenorphine (2 NICUs), chlorpromazine (1 non-ICU), and lorazepam or other benzodiazepines (1 NICU).

DISCUSSION

The opioid crisis has affected many infants across the United States, and critical gaps remain in our knowledge of the best practices for diagnosis of NOWS and care of infants with NOWS. The strength of the ACT NOW collaborative is to join the neonatal

expertise of the NRN with the ISPCTN's mission of engaging rural and underserved areas in clinical trials. This is of particular importance given the disproportionate increase of NOWS in rural compared with urban settings.²⁸ The ACT NOW Clinical Practice Survey sites reported protocols for many elements of NOWS care, including NOWS scoring (98% of NICUs and 86% of non-ICUs), pharmacologic treatment (92% of NICU and 64% of non-ICUs), and nonpharmacologic care (79% of NICUs and 79% non-ICUs). This appears to represent an increase in several domains compared with the results of the BORN survey in 2015, in which 93% of respondents had a NOWS scoring protocol and 72% had protocols for pharmacologic care.¹⁹ Similarly, we observed a higher frequency of NOWS scoring protocols compared with that in a 2014 study in the Vermont Oxford Network, in which 77% of units reported NOWS scoring standardization.¹⁷ A majority of sites in our survey used the Finnegan scoring system or a modification of it, similar to findings of previous studies.^{17–20}

As the incidence of NOWS has increased so has the use of NICUs to care for these newborns, often separating the mother-infant dyad.²⁹ In this survey, pharmacologic treatment occurred most often in the intensive care setting, with the majority occurring in level 2 to level 4 NICUs, similar to that reported in other NOWS studies.^{3,19,24}

TABLE 3 Types of Nonpharmacologic Therapy Provided

Which Nonpharmacologic Therapies Does Your Unit Use for Stabilization and Treatment of Infants With In Utero Opioid Exposure?	NICU		Non-ICU	
	No. Units (n = 48)	Units, % (95% CI)	No. Units (n = 14)	Units, % (95% CI)
Rooming-in with mother	29	60 (46–73)	9	64 (39–84)
Breastfeeding ^a	47	98 (89–100)	10	71 (45–88)
Swaddling	47	98 (89–100)	12	86 (60–96)
Cuddlers ^b	36	75 (61–85)	6	43 (21–67)
Infant massage	10	21 (12–34)	2	14 (4–40)
Positioning and comfort measures	42	88 (75–94)	11	79 (52–92)
Avoiding overstimulation	45	94 (83–98)	12	86 (60–96)
High-calorie nutrition, hypercaloric formula	19	40 (27–54)	6	43 (21–67)

Units may have reported >1 type of nonpharmacologic care. There were 62 responding units in total. Seven sites indicated “other” and entered free text to describe other types of nonpharmacologic care, including elemental formula if no breast milk was available, ear muffs, dark rooms, single rooms, skin-to-skin contact, environmental control, high-calorie nutrition only if there is significant weight loss, and nonpharmacologic therapy as directed by physical and/or occupational therapy or child-life consultations.

^a $P < .05$; Fisher's exact test.

^b $P < .05$; the χ^2 test was used for comparison between the percentage of NICUs that responded affirmatively to each question and the percentage of non-ICUs that responded affirmatively to each question.

Buprenorphine, which has been associated with shortened length of stay in some studies, was not widely reported in this sample.⁵

The use of nonpharmacologic interventions (in particular, keeping the mother with her infant) has proven to ameliorate NOWS symptoms. Higher rates of nonpharmacologic care protocols were reported in this study compared with the BORN survey. We observed that 79% of units reported protocols for nonpharmacologic care, compared with 58% of units in the BORN survey.¹⁹ More than 60% of the ACT NOW Clinical Practice Survey units reported using nonpharmacologic practices such as rooming-in, breastfeeding, positioning and comforting, swaddling, and avoiding overstimulation. The apparent increase in nonpharmacologic care practices reported may be attributable to the increasing evidence of their success, with recent studies revealing the benefits of parental presence and rooming-in on postnatal opioid exposure, hospital length of stay, breastfeeding rates, discharge from the hospital with family, and/or hospital cost.^{12,30} However, only 15% of centers in the ACT NOW Clinical Practice Survey reported rooming-in during pharmacologic treatment. Overall, the non-ICUs in our survey reported fewer protocols for pharmacologic care and weaning compared with NICUs. This likely reflects the finding that pharmacologic care in general occurs more often in the NICU setting and that care in this setting is often more protocolized.^{3,31,32} Non-ICU responders were also less likely to report the use of certain nonpharmacologic care measures, such as cuddlers and breastfeeding, which was somewhat unexpected and may be affected by the small number of non-ICU responders included in this sample.

There are several limitations to this survey. First, because this was intended as a clinical practice assessment for a specific clinical trial platform, only ISPCTN and NRN sites were surveyed, and the instrument was not validated, which limits the generalizability of our results. In particular, the oversampling of NICUs at academic medical centers may contribute to a higher proportion of sites with protocolized care and management in the ICU setting. There

may be additional units at the participating institutions that provide care for infants with NOWS but did not respond to this survey. In addition, the brevity of the survey offered little opportunity for details regarding the implementation of protocols to guide NOWS care at the participating sites. Variability in respondents' perceptions and reporting of NOWS care in a particular unit may have influenced the results of the survey. In addition, respondents' reports may not account for practitioner variability within a given hospital or site. A follow-up study, ACT NOW Current Experience, is being used to obtain infant-level data on individual- and site-level variations in NOWS care within the ISPCTN and NRN collaborative to address several of these limitations.

CONCLUSIONS

The care of infants exposed to opioids is developing in response to the opioid crisis. These broad changes reflect a response by medical care providers to an evolving children's health problem. Observed variations in care between NICUs and non-ICUs reveal opportunities for targeted interventions in training and standardized care plans in non-ICU sites, given the benefits associated with standardization. However, many gaps remain in our understanding of which elements of standardized care may be most beneficial, of which variations might be beneficial for certain infants, and of the long-term effects of pharmacologic and nonpharmacologic treatment options for NOWS symptoms. This survey reveals the importance of multisite clinical studies, particularly those that engage participants in the highest-risk areas, to generate data that may be generalizable to a wide range of practices. Future ACT NOW studies can be used to assess the prevalence of NOWS in different regions of the country, describe individual- and site-level variations in care for infants with NOWS, and help develop clinical trials that impact the policies and practices that guide NOWS diagnosis and treatment in the United States.

Acknowledgments

The following investigators, in addition to those listed as authors, participated in this

study: ISPCTN Steering Committee Chair: Jill Joseph, MD (University of California, Davis Health); NRN Steering Committee Chair: Richard A. Polin, MD (Columbia University); Alaska Native Tribal Health Consortium, Alaska Native Medical Center, Alaska Regional Hospital, Fairbanks Memorial Hospital, and The Children's Hospital at Providence: Lily Lou, MD, Laura Brunner, MD, Dianne Gillis, MD, and Mary Herrick, MD; Alpert Medical School of Brown University and Women and Infants Hospital of Rhode Island: Adam Czynski, MD, Abbot R. Laptook, MD, Martin Keszler, MD, Angelita M. Hensman, PhD, MS, RNC-NIC, Kristin M. Basso, MS, BSN, Andrea M. Knolls, Suzy Ventura, and Elisa Vieira, RN, BSN; Arkansas Children's Research Institute, University of Arkansas for Medical Sciences, and University of Arkansas: Jennifer Andrews, MD, and William Greenfield, MD; Case Western Reserve University, Rainbow Babies and Children's Hospital: Michele C. Walsh, MD, MS, Anna Marie Hibbs, MD, and Nancy S. Newman, BA, RN; Cincinnati Children's Hospital Medical Center, University Hospital, and Good Samaritan Hospital: Brenda B. Poindexter, MD, MS, Kurt Schibler, MD, Kate Bridges, MD, Barbara Alexander, RN, Cathy Grisby, BSN, CCRC, Jody Hessling, RN, Estelle E. Fischer, MHSA, MBA, Lenora D. Jackson, CRC, Kristin Kirker, CRC, and Greg Muthig, BS; Dartmouth College, Dartmouth-Hitchcock Medical Center, and Children's Hospital at Dartmouth-Hitchcock Medical Center: Alison Holmes, MD; Duke University School of Medicine, University Hospital, University of North Carolina at Chapel Hill, Duke Regional Hospital, and WakeMed Health and Hospitals: Wayne Price, MD, Ronald N. Goldberg, MD, C. Michael Cotten, MD, MHS, Kimberley A. Fisher, PhD, FNP-BC, IBCLC, Joanne Finkle, RN, JD, Matthew M. Laughon, MD, MPH, Carl L. Bose, MD, Janice Bernhardt, MS, RN, Gennie Bose, RN, and Stephen D. Kicklighter, MD; Emory University, Children's Healthcare of Atlanta, Grady Memorial Hospital, and Emory University Hospital Midtown: David P. Carlton, MD, Yvonne Loggins, RN, BSN, and Diane Bottcher, RN, MN; NICHD: Andrew Bremer, MD, and Stephanie Wilson Archer, MA; Louisiana State University and Tulane Lakeside Hospital for Women and Children:

Jay P. Goldsmith, MD; Nemours/Alfred I. duPont Hospital for Children and Christiana Care Health System: David Paul, MD; McGovern Medical School at The University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, and Lyndon Baines Johnson General Hospital/Harris County Hospital District: Jon E. Tyson, MD, MPH, Amir M. Khan, MD, Barbara J. Stoll, MD, Emily K. Stephens, RN, BSN, Janice John, CPNP, Daniel Sperry, RN, and Patti L. Pierce Tate, RCP; Nationwide Children's Hospital, Research Institute at Nationwide Children's Hospital, The Ohio State University Wexner Medical Center, The Ohio State College of Medicine, and Center for Perinatal Research: Erin Keels, DNP, APRN, NNP-BC, Pablo J. Sánchez, MD, Leif D. Nelin, MD, Sudarshan R. Jadcherla, MD, Patricia Luzader, RN, Julie Gutentag, RN, Margaret Sullivan, BA, Jennifer L. Grothouse, RN, Melanie Stein, BBA, RRT, Erna Clark, BA, and Rox Ann Sullivan, BSN; Rhode Island Hospital and Kent Hospital: Nicholas G. Guerina, MD, PhD; RTI International: Dennis Wallace, PhD, Jamie E. Newman, PhD, MPH, Jeanette O'Donnell Auman, BS, Marie G. Gantz, PhD, Carolyn M. Petrie Huitema, MS, CCRP, and Kristin M. Zaterka-Baxter, RN, BSN, CCRP; Stanford University, Dominican Hospital, El Camino Hospital, and Lucile Packard Children's Hospital: Krisa P. Van Meurs, MD, Valerie Y. Chock, MD, MS Epi, M. Bethany Ball, BS, CCRC, and Melinda S. Proud, RCP; University of Alabama at Birmingham Health System and Children's Hospital of Alabama: Waldemar A. Carlo, MD, Namasivayam Ambalavanan, MD, and Shirley S. Cosby, RN, BSN; University of Hawaii at Manoa and the Kapiolani Medical Center for Women and Children: Charles Neal, MD, PhD, and Men-Jean Lee, MD; University of Iowa Stead Family Children's Hospital: Jonathan Klein, MD, Edward F. Bell, MD, Tarah T. Colaizy, MD, MPH, Karen J. Johnson, RN, BSN, Jacky R. Walker, RN, and Kelly E. Wood, MD; University of Kansas Medical Center, the University of Kansas Health System, and Children's Mercy Kansas City: Kourtney Bettinger, MD, Teresa Kilkeny, DNP, PNP-PC, Krishna Dummula, MD, and Danielle Reed, MD; University of Louisville, Norton Hospital Newborn Nursery, Norton Children's Hospital, and University of Louisville Hospital: Sara Watson, MD, MS,

Janice Sullivan, MD, and Jackie Perry Boyd, RN, BSN; University of New Mexico Health Sciences Center: Kristi L. Watterberg, MD, Janell F. Fuller, MD, and Jean R. Lowe, PhD; University of Mississippi Medical Center: Mobolaji Famuyide, MD, and Lauren Tucker, MD; University of Montana, Community Medical Center, Montana Children's Medical Center, St Vincent Healthcare, and Billings Clinic: Jeff Cooper, MD, Alison Rentz, MD, Mark Kaneta, MD, and Bonnie E. Stephens, MD; University of Nebraska Medical Center: Ann Anderson Berry, MD; University of Oklahoma Health Sciences Center, Comanche County Memorial Hospital, and University of Oklahoma Children's Hospital: Abhishek Makkar, MD, and Kimberly D. Ernst, MD, MSMI, FAAP; University of Pennsylvania, Hospital of the University of Pennsylvania, Pennsylvania Hospital, Children's Hospital of Philadelphia, and Virtua Voorhees Hospital: Karen Puopolo, MD, Michael Posencheg, MD, Elizabeth Fong-deLeon MD, Eric C. Eichenwald, MD, Sara B. DeMauro, MD, MSCE, Soraya Abbasi, MD, Toni Mancini, RN, BSN, CCRC, and Dara M. Cucinotta, RN; University of Rochester Medical Center, Golisano Children's Hospital, University of Buffalo, Women's and Children's Hospital of Buffalo, and State University of New York at Buffalo: Praveen Chandrasekharan, MD, Ann Marie Scorsone, MS, Carl T. D'Angio, MD, Ronnie Guillet, MD, PhD, Anne Marie Reynolds, MD, MPH, Michael G. Sacilowski, BS, Cassandra A. Horihan, MS, and Ashley Williams, MEd; University of South Carolina at Columbia, Spartanburg Medical Center, East Cooper Medical Center, Medical University Of South Carolina, McLeod Regional Medical Center, and Palmetto Health Richland: Laura Basile, MD, MSPH, Douglas Moeckel, MD, Julie Ross, MD, K. Lee, MD, and Brian Wood, MD; University of Texas Southwestern Medical Center at Dallas, Parkland Health and Hospital System, and Children's Medical Center Dallas: Myra H. Wyckoff, MD, Luc P. Brion, MD, Diana M. Vasil, RNC, NIC, LiJun Chen, PhD, RN, Alicia Guzman, and Lizette E. Lee, RN; University of Utah Medical Center, Intermountain Medical Center, McKay-Dee Hospital, Primary Children's Medical Center, and Utah Valley Hospital: Erick Gerday, MD, Camille Fung, MD, Bradley A. Yoder, MD, Mark Sheffield,

MD, Manndi C. Loertscher, BS, CCRP, and Carrie A. Rau, RN, BSN, CCRC; University of Vermont and State Agricultural College and the University of Vermont Children's Hospital: Charles Mercier; and West Virginia University.

The National Institutes of Health, the NICHD, and the National Center for Advancing Translational Sciences provided support for the NRN, and the National Institutes of Health, Office of the Director; Environmental Influences on Child Health Outcomes (ECHO) Program provided support for the ISPCTN. Although NICHD and ECHO staff had input in the study design, conduct, analysis, and article drafting, the comments and views of the authors do not necessarily represent the views of the NICHD or the ECHO program, the National Institutes of Health, the US Department of Health and Human Services, or the US Government. Data were collected at participating sites of the NICHD NRN, and participating sites of the ECHO ISPCTN were transmitted to the University of Arkansas for Medical Sciences, the DCOC for this study. Dr Jeannette Lee and Dr Snowden (DCOC Principal Investigators) had full access to the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. We are indebted to our medical and nursing colleagues who agreed to take part in this study.

REFERENCES

1. Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012 [published correction appears in *J Perinatol*. 2015;35(8):667]. *J Perinatol*. 2015;35(8):650–655
2. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. *JAMA*. 2012;307(18):1934–1940
3. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. *N Engl J Med*. 2015;372(22):2118–2126

4. Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal [published correction appears in *Pediatrics*. 2014; 133(5):937]. *Pediatrics*. 2012;129(2). Available at: www.pediatrics.org/cgi/content/full/129/2/e540
5. Winkelman TNA, Villapiano N, Kozhimannil KB, Davis MM, Patrick SW. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004-2014. *Pediatrics*. 2018;141(4):e20173520
6. Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid use disorder documented at delivery hospitalization - United States, 1999-2014. *MMWR Morb Mortal Wkly Rep*. 2018;67(31):845-849
7. Ko JY, Wolicki S, Barfield WD, et al. CDC Grand Rounds: public health strategies to prevent neonatal abstinence syndrome. *MMWR Morb Mortal Wkly Rep*. 2017;66(9):242-245
8. Hall ES, Wexelblatt SL, Crowley M, et al; OCHNAS Consortium. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. *Pediatrics*. 2014;134(2). Available at: www.pediatrics.org/cgi/content/full/134/2/e527
9. Hall ES, Wexelblatt SL, Crowley M, et al; OCHNAS Consortium. Implementation of a neonatal abstinence syndrome weaning protocol: a multicenter cohort study. *Pediatrics*. 2015;136(4). Available at: www.pediatrics.org/cgi/content/full/136/4/e803
10. Walsh MC, Crowley M, Wexelblatt S, et al; Ohio Perinatal Quality Collaborative. Ohio perinatal quality collaborative improves care of neonatal narcotic abstinence syndrome. *Pediatrics*. 2018;141(4):e20170900
11. Cook CL, Dahms SK, Meiers SJ. Enhancing care for infants with neonatal abstinence syndrome: an evidence-based practice approach in a rural midwestern region. *Worldviews Evid Based Nurs*. 2017;14(5):422-423
12. MacMillan KDL, Rendon CP, Verma K, Riblet N, Washer DB, Volpe Holmes A. Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. *JAMA Pediatr*. 2018;172(4):345-351
13. Grossman MR, Berkowitz AK, Osborn RR, et al. An initiative to improve the quality of care of infants with neonatal abstinence syndrome. *Pediatrics*. 2017; 139(6):e20163360
14. Grossman MR, Lipshaw MJ, Osborn RR, Berkowitz AK. A novel approach to assessing infants with neonatal abstinence syndrome. *Hosp Pediatr*. 2018;8(1):1-6
15. Whalen BL, Grossman MR, Whatley C, et al. Inter- and intra-rater reliability of the Eating, Sleeping, Consoling (ESC) care tool for Neonatal Abstinence Syndrome (NAS). In: Proceedings from the 2018 Annual Meeting of the Pediatric Academic Societies; May 5-8, 2018; Toronto, Canada
16. Wachman EM, Grossman M, Schiff DM, et al. Quality improvement initiative to improve inpatient outcomes for neonatal abstinence syndrome. *J Perinatol*. 2018; 38(8):1114-1122
17. Patrick SW, Schumacher RE, Horbar JD, et al. Improving care for neonatal abstinence syndrome. *Pediatrics*. 2016; 137(5):e20153835
18. Mehta A, Forbes KD, Kuppala VS. Neonatal abstinence syndrome management from prenatal counseling to postdischarge follow-up care: results of a national survey. *Hosp Pediatr*. 2013; 3(4):317-323
19. Bogen DL, Whalen BL, Kair LR, Vining M, King BA. Wide variation found in care of opioid-exposed newborns. *Acad Pediatr*. 2017;17(4):374-380
20. Murphy K, Goo H, Warre R, Shah V, Dow K. Variations and similarities in clinical management of neonatal abstinence syndrome: findings of a Canadian survey. *Paediatr Child Health*. 2017;22(3): 148-152
21. Whalen BL, Holmes AV, Blythe S. Models of care for neonatal abstinence syndrome: what works? *Semin Fetal Neonatal Med*. 2019;24(2):121-132
22. Snowden J, Darden P, Palumbo P, Saul P, Lee J; IDEa States Pediatric Clinical Trials Network. The institutional development award states pediatric clinical trials network: building research capacity among the rural and medically underserved. *Curr Opin Pediatr*. 2018; 30(2):297-302
23. Higgins RD, Shankaran S. The Neonatal Research Network: history since 2003, future directions and challenges. *Semin Perinatol*. 2016;40(6):337-340
24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2): 377-381
25. Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacotherapy. In: Nelson NM, ed. *Current Therapy in Neonatal-Perinatal Medicine*. 2nd ed. Hamilton, Canada: BC Decker; 1990
26. Zahorodny W, Rom C, Whitney W, et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. *J Dev Behav Pediatr*. 1998;19(2):89-93
27. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. *Addict Dis*. 1975;2(1-2): 141-158
28. Villapiano NL, Winkelman TN, Kozhimannil KB, Davis MM, Patrick SW. Rural and urban differences in neonatal abstinence syndrome and maternal opioid use, 2004 to 2013. *JAMA Pediatr*. 2017;171(2):194-196
29. Howard MB, Schiff DM, Penwill N, et al. Impact of parental presence at infants' bedside on neonatal abstinence syndrome. *Hosp Pediatr*. 2017;7(2):63-69
30. Disher T, Gullickson C, Singh B, et al. Pharmacological treatments for neonatal abstinence syndrome: a systematic review and network meta-analysis. *JAMA Pediatr*. 2019;173(3): 234-243

31. Wielenga JM, van den Hoogen A, van Zanten HA, Helder O, Bol B, Blackwood B. Protocolized versus non-protocolized weaning for reducing the duration of invasive mechanical ventilation in newborn infants. *Cochrane Database Syst Rev.* 2016;(3): CD011106
32. Chang SY, Sevransky J, Martin GS. Protocols in the management of critical illness. *Crit Care.* 2012;16(2): 306